BlueWhale Bio, Inc. filed a Form D with the Securities and Exchange Commission on 2025-10-16.
BlueWhale Bio, Inc. filed a Form D notice of an exempt securities offering with the SEC on October 16, 2025. The filing reports $5M sold. Its industry group is Biotechnology. It names Peter Keller (Executive Officer, Director), Paula Cannon (Director), Elaine Heron (Director) (SEC Form D, October 16, 2025).
Is this your company?
Sell to companies like BlueWhale Bio, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2025-10-16 · the record
Pitching, partnering or investing alongside them? See who really runs and owns BlueWhale Bio, Inc.
Free to see. No signup.
More on the people and the money behind BlueWhale Bio, Inc., from the filings we hold.
Biotechnology raises by companies based in Pennsylvania, filed in October 2025, largest first.
Get an email when BlueWhale Bio, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when BlueWhale Bio, Inc. raises, hires or launches. No email unless you switch it on.
Watch BlueWhale Bio, Inc. →Get the full cited report on BlueWhale Bio, Inc.
What the filing shows about BlueWhale Bio, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on BlueWhale Bio, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
The filing gives BlueWhale Bio, Inc.'s address as 2929 Arch St, Philadelphia, PA 19104.
Saved here on this device in the meantime, so nothing is lost either way.
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
BlueWhale Bio, Inc. is a registered filer with the SEC (CIK 1989669) and has filed since 2025-10-16. 1 filing is on record, the latest on 2025-10-16.
A filing shows the company exists and what it reports about itself. It is not an audit or a rating.
BlueWhale Bio, Inc.'s Form D of 2025-10-16 names Peter Keller, Paula Cannon, Elaine Heron and 2 more as its officers, directors or promoters.
Its new offerings report $5M sold across 1 offering, as its own filings state.
Trailing twelve months. 766 filings in Biotechnology, totalled by week.
Checked away from the filing. What is below does not come from the record on sec.gov.
Cell Therapy Success Starts Here Synecta™ Activation and Expansion Solutions
The title and description the site itself served, answering 200. Not a cached copy and not the company's directory entry — what was live when we asked.
Peter Keller is named as Executive Officer and Director on the Form D that BlueWhale Bio, Inc. filed with the SEC on 16 October 2025, one of 5 people that filing names.
Paula Cannon is named as Director on the Form D that BlueWhale Bio, Inc. filed with the SEC on 16 October 2025, one of 5 people that filing names.
Elaine Heron is named as Director on the Form D that BlueWhale Bio, Inc. filed with the SEC on 16 October 2025, one of 5 people that filing names.
Paul Meister is named as Director on the Form D that BlueWhale Bio, Inc. filed with the SEC on 16 October 2025, one of 5 people that filing names.
Beate Mueller-Tiemann is named as Director on the Form D that BlueWhale Bio, Inc. filed with the SEC on 16 October 2025, one of 5 people that filing names.
5 people named on the filing — 1 holding an executive role and 4 as directors only.
Named as of the 2025-10-16 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
No investor is drawn from a Form D — the form states how many invested and never who.
What the filing shows about BlueWhale Bio, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on BlueWhale Bio, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on BlueWhale Bio, Inc. covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist BlueWhale Bio, Inc.You get an alert in MentionFox the next time this company shows up.
If you're behind BlueWhale Bio, Inc.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov, and from the company's own site, read directly on 2026-10-30 (bluewhale.bio).
Each opens in a new tab, filled in for BlueWhale Bio, Inc.. With no account yet, you sign up free and land on the result.
On these lists: Biotech raises in Philadelphia
Share your raise. This card is drawn from the company's own Form D filing, and sharing needs no account.
https://mentionfox.com/funding/bluewhale-bio-inc-form-d-25000001